Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 5 of 5 publications.

Mannion L, Watson V, Mullassery V, Nair R, Charlton T, Northover M, Enting D, Van Hemelrijck M, Khan MS, Thurairaja R, Amery S, Chatterton K, Smith K, Hughes S. Treatment preferences of patients with muscle invasive bladder cancer: a discrete choice experiment. BJUI Compass. 2024 Oct 11;5(11):1059-68. doi: 10.1002/bco2.443

Menon AP, Villanueva H, Meraviglia-Crivelli D, van Santen HM, Hellmeier J, Zheleva A, Nonateli F, Peters T, Wachsmann TLA, Hernandez-Rueda M, Huppa JB, Schutz GJ, Sevcsik E, Moreno B, Pastor F. CD3 aptamers promote expansion and persistence of tumor-reactive T cells for adoptive T cell therapy in cancer. Mol Ther Nucleic Acids. 2024 Apr 23;35(2):102198. doi: 10.1016/j.omtn.2024.102198

Meraviglia-Crivelli D, Villanueva H, Menon AP, Zheleva A, Moreno B, Villalba-Esparza M, Pastor F. A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progression. Mol Ther Nucleic Acids. 2022 Jul 20;29:413-25. doi: 10.1016/j.omtn.2022.07.017

Sola M, Menon AP, Moreno B, Meraviglia-Crivelli D, Soldevilla MM, Carton-Garcia F, Pastor F. Aptamers against live targets: is in vivo SELEX finally coming to the edge? Mol Ther Nucleic Acids. 2020 Sep 4;21:192-204. doi: 10.1016/j.omtn.2020.05.025

Herring WL, Herrmann JW. The single-day surgery scheduling problem: sequential decision-making and threshold-based heuristics. OR spectrum: quantitative approaches in management. 2012 Apr 1;34(2):429-59.